

Dear

FREEDOM OF INFORMATION – CANCER TREATMENT

I write in response to your request for information in relation to cancer treatment in NHS Lothian.

Question:

1. How many ovarian cancer patients (any stage) have been treated in the last 3 months with: Paclitaxel in combination with a platinum-based compound; Platinum-based therapy alone (cisplatin or carboplatin); Bevacizumab in combination with paclitaxel and carboplatin; Olaparib; Olaparib + Bevacizumab; Niraparib; Rucaparib.

Answer:

The information you have requested is detailed in the table below. I have not released numbers of 5 or fewer in the table, as this information could lead to the identification of the individuals involved. Since we do not have their consent to release their personal data, the information is exempt under section 38 of the Freedom of Information (Scotland) Act 2002 as to provide it would breach the principles of the Data Protection Act 2018.

Ovarian Cancer Treatment, NHS Lothian	
Treatment	Number of patients
Paclitaxel in combination with a platinum-based compound	26
Platinum-based therapy alone (cisplatin or carboplatin)	7
Bevacizumab in combination with paclitaxel and carboplatin	12
Olaparib	12
Olaparib + Bevacizumab	≤5
Niraparib	9
Rucaparib	0

Question:

2. Does your trust participate in any clinical trials for the treatment of ovarian cancer? If so, please provide the name of each trial along with the number of patients taking part.

Answer:

The table below details the clinical trials NHS Lothian is participating in. I have not released numbers of 5 or fewer in the table, as this information could lead to the identification of the

individuals involved. Since we do not have their consent to release their personal data, the information is exempt under section 38 of the Freedom of Information (Scotland) Act 2002 as to provide it would breach the principles of the Data Protection Act 2018.

Ovarian Cancer Treatment Trials, NHS Lothian	
Name of trial	Participants recruited
ACTOv, A multicentre phase II randomised controlled trial to evaluate the efficacy of Adaptive Therapy (AT) with carboplatin, based on changes in CA125, in patients with relapsed platinum-sensitive high grade serous or high grade endometrioid ovarian cancer	6
RAMP301, A Phase 3, Randomized, Open-Label Study of Combination Therapy with Avutometinib plus Defactinib Versus Investigator's Choice of Treatment in Patients with Recurrent Low-Grade Serous Ovarian Cancer (LGSOC)	≤5
EPSILOGEN, A Phase Ib, Open-Label Trial of MOv18 IgE in Patients with Advanced Ovarian Cancer	≤5
SOPRANO, Stereotactic radiotherapy alone or followed by niraparib for oligometastases or oligoprogression in ovarian cancer following PARP inhibitor therapy	0
TroFuse-022, A Phase 3, Randomized, Open-label, Multicenter Study to Evaluate the Efficacy and Safety of Sacituzumab Tirumotecan (MK-2870) Maintenance Treatment With or Without Bevacizumab Versus Standard of Care After Second-line Platinum-based Doublet Chemotherapy in Participants With Platinum-sensitive Recurrent Ovarian Cancer (ENGOT-ov84/GOG-3103)	0
ACTOv, A multicentre phase II randomised controlled trial to evaluate the efficacy of Adaptive Therapy (AT) with carboplatin, based on changes in CA125, in patients with relapsed platinum-sensitive high grade serous or high grade endometrioid ovarian cancer	6

I hope the information provided helps with your request.

If you are unhappy with our response to your request, you do have the right to request us to review it. Your request should be made within 40 working days of receipt of this letter, and we will reply within 20 working days of receipt. If our decision is unchanged following a review and you remain dissatisfied with this, you then have the right to make a formal complaint to the Scottish Information Commissioner within 6 months of receipt of our review response. You can do this by using the Scottish Information Commissioner's Office online appeals service at <https://www.foi.scot/appeal>. If you remain dissatisfied with the Commissioner's response you then have the option to appeal to the Court of Session on a point of law.

If you require a review of our decision to be carried out, please write to the reviewer at the address at the top of this letter. The review will be undertaken by a Reviewer who was not involved in the original decision-making process.

FOI responses (subject to redaction of personal information) may appear on NHS Lothian's Freedom of Information website at: <https://org.nhslothian.scot/FOI>

Yours sincerely

ALISON MACDONALD
Executive Director of Nursing Midwifery and AHPs
Cc: Chief Executive